Intellia Therapeutics (NTLA) EBITDA (2015 - 2026)
Intellia Therapeutics (NTLA) EBITDA from Mar 31, 2015 to Mar 31, 2026. The TTM Intellia Therapeutics (NTLA) EBITDA is -$411M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Intellia Therapeutics (NTLA) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -22.52% |
| 3 Years TTM | -0.54% |
| 5 Years TTM | +23.42% |
| 10 Years TTM | +36.41% |
| All Time TTM | +36.42% |
Annual EBITDA change of Intellia Therapeutics (NTLA)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$98M | -77.20% |
| 2025 | -$431M | -17.70% |
| 2024 | -$524M | +3.49% |
| 2023 | -$506M | +12.37% |
| 2022 | -$451M | +72.67% |
| 2021 | -$261M | +100.32% |
| 2020 | -$130M | +29.26% |
| 2019 | -$101M | +16.63% |
| 2018 | -$86M | +29.82% |
| 2017 | -$67M | +114.36% |
| 2016 | -$31M | +137.39% |
| 2015 | -$13M | N/A |
Comparison Intellia Therapeutics (NTLA) five years EBITDA CAGR with competitors
Intellia Therapeutics (NTLA) five years EBITDA CAGR is 23.42%.